FY2028 Earnings Forecast for PolyPid Issued By HC Wainwright

PolyPid Ltd. (NASDAQ:PYPD) – Investment analysts at HC Wainwright boosted their FY2028 earnings per share estimates for PolyPid in a research report issued to clients and investors on Wednesday, February 11th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of $0.21 for the year, up from their prior forecast of $0.20. HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for PolyPid’s FY2030 earnings at $4.02 EPS.

PolyPid (NASDAQ:PYPD) last released its quarterly earnings data on Wednesday, February 11th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.07).

PYPD has been the subject of several other research reports. Citigroup restated a “market outperform” rating on shares of PolyPid in a research report on Monday, December 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of PolyPid in a research report on Monday, December 29th. Roth Mkm decreased their price objective on shares of PolyPid from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Finally, Wall Street Zen upgraded PolyPid from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $12.25.

PolyPid Stock Down 1.3%

Shares of PYPD opened at $4.62 on Thursday. The company has a market capitalization of $73.44 million, a price-to-earnings ratio of -1.55 and a beta of 1.52. PolyPid has a 52-week low of $2.30 and a 52-week high of $5.12. The stock has a 50 day moving average price of $4.35 and a 200 day moving average price of $3.80.

Institutional Investors Weigh In On PolyPid

A number of institutional investors and hedge funds have recently made changes to their positions in PYPD. Lumbard & Kellner LLC acquired a new stake in shares of PolyPid during the second quarter worth about $135,000. AIGH Capital Management LLC raised its stake in PolyPid by 27.0% during the 2nd quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock valued at $4,215,000 after acquiring an additional 253,727 shares during the last quarter. HighTower Advisors LLC acquired a new stake in PolyPid during the 4th quarter worth approximately $44,000. Finally, BNP Paribas Financial Markets grew its stake in shares of PolyPid by 56.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock valued at $32,000 after purchasing an additional 3,500 shares during the last quarter. 26.47% of the stock is owned by hedge funds and other institutional investors.

PolyPid News Summary

Here are the key news stories impacting PolyPid this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” and published aggressive long-range forecasts (FY2030 EPS $4.02) and a $13 price target, implying substantial upside versus current levels. This institutional bullish view supports investor optimism about long-term value. Article Title
• Positive Sentiment: Corporate update: PolyPid says it is in advanced-stage U.S. commercial partnership discussions for its D-PLEX100 product — a potential near‑term commercial catalyst that could materially change revenue prospects if a deal is signed. Article Title
• Positive Sentiment: Earnings call highlighted an actionable 2026 catalyst (management tone described as upbeat), which supports the positive analyst outlook if milestones are met. Article Title
• Neutral Sentiment: HC Wainwright modestly increased its FY2028 EPS view to $0.21 (from $0.20) — a small modeling tweak that supports the analyst’s longer-term thesis but is not a near-term revenue confirmation.
• Negative Sentiment: Q4 EPS missed expectations: PolyPid reported ($0.41) vs. consensus ($0.34), underscoring current profitability challenges and contributing to downward pressure on the stock. Article Title
• Negative Sentiment: Short interest rose ~44.8% in January (to ~27.9k shares), a signal of growing bearish positioning; although absolute short percentage is small (~0.2% of float), the increase can amplify near-term downside on negative news.

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.